These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 36151978)

  • 1. Longitudinal use of patient reported outcomes in pediatric leukemia and lymphoma reveals clinically relevant symptomatic adverse events.
    Jacobs SS; Withycombe JS; Castellino SM; Lin L; Mack JW; McFatrich M; Baker JN; Freyer DR; Maurer SH; Mowbray C; Hinds PS; Reeve BB
    Pediatr Blood Cancer; 2022 Dec; 69(12):e29986. PubMed ID: 36151978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the caregiver Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure.
    Reeve BB; McFatrich M; Lin L; Lucas NR; Mack JW; Jacobs SS; Withycombe JS; Baker JN; Freyer DR; Hinds PS
    Cancer; 2021 May; 127(9):1483-1494. PubMed ID: 33332590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials.
    Freyer DR; Lin L; Mack JW; Maurer SH; McFatrich M; Baker JN; Jacobs SS; Lucas N; Withycombe JS; Tomlinson D; Villabroza KR; Waldron MK; Hinds PS; Reeve BB
    J Clin Oncol; 2022 May; 40(15):1623-1634. PubMed ID: 35294262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
    Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
    J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
    Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptom Adverse Events and Quality of Life of Children With Advanced Cancer: Results From a Longitudinal Study Using the Pediatric Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events.
    Grinde K; Raybin JL; Ward J; Smith C; Brown R; Montgomery KE
    J Pediatr Hematol Oncol Nurs; 2024; 41(1):5-15. PubMed ID: 37697734
    [No Abstract]   [Full Text] [Related]  

  • 7. Recommended scoring approach for the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events.
    Hinds PS; Pinheiro LC; McFatrich M; Waldron M; Baker JN; Mowbray C; Maurer SH; Cheng Y; Reeve BB; Wang J
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29452. PubMed ID: 34866311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjective Toxicity Profiles of Children in Treatment for Cancer: A New Guide to Supportive Care?
    Hinds PS; Weaver MS; Withycombe JS; Baker JN; Jacobs SS; Mack JW; Maurer SH; McFatrich M; Pinheiro LC; Reeve BB; Wang J
    J Pain Symptom Manage; 2021 Jun; 61(6):1188-1195.e2. PubMed ID: 33096220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients, caregivers, and clinicians differ in performance status ratings: Implications for pediatric cancer clinical trials.
    Maurer SH; Hinds PS; Reeve BB; Mack JW; McFatrich M; Lin L; Withycombe JS; Jacobs SS; Baker JN; Castellino SM; Freyer DR
    Cancer; 2021 Oct; 127(19):3664-3670. PubMed ID: 34196962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment.
    Reeve BB; McFatrich M; Mack JW; Pinheiro LC; Jacobs SS; Baker JN; Withycombe JS; Lin L; Mann CM; Villabroza KR; Hinds PS
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28160. PubMed ID: 31904157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
    Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
    J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.
    Speck RM; Lenderking WR; Shaw JW
    J Patient Rep Outcomes; 2017; 2():35. PubMed ID: 30175317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROMIS pediatric measures validated in a longitudinal study design in pediatric oncology.
    Hinds PS; Wang J; Cheng YI; Stern E; Waldron M; Gross H; DeWalt DA; Jacobs SS
    Pediatr Blood Cancer; 2019 May; 66(5):e27606. PubMed ID: 30663254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma.
    Wang XS; Giralt SA; Mendoza TR; Engstrom MC; Johnson BA; Peterson N; Broemeling LD; Cleeland CS
    J Clin Oncol; 2002 Mar; 20(5):1319-28. PubMed ID: 11870175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains.
    Ellis GK; Chapman H; Manda A; Salima A; Itimu S; Banda G; Seguin R; Manda G; Butia M; Huibers M; Ozuah N; Tilly A; Stover AM; Basch E; Gopal S; Reeve BB; Westmoreland KD
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29257. PubMed ID: 34339099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
    McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
    Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Longitudinal Study of PROMIS Pediatric Symptom Clusters in Children Undergoing Chemotherapy.
    Wang J; Jacobs S; Dewalt DA; Stern E; Gross H; Hinds PS
    J Pain Symptom Manage; 2018 Feb; 55(2):359-367. PubMed ID: 28865867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voices of children and adolescents on phase 1 or phase 2 cancer trials: A new trial endpoint?
    Hinds PS; Wang J; Stern ED; Macpherson CF; Wharton CM; Okorosobo R; Cheng YI; Gross HE; Meany HJ; Jacobs S
    Cancer; 2017 Oct; 123(19):3799-3806. PubMed ID: 28581685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translation, psychometric validation, and baseline results of the Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures to assess health-related quality of life of patients with pediatric lymphoma in Malawi.
    Westmoreland K; Reeve BB; Amuquandoh A; van der Gronde T; Manthalu O; Correia H; Stanley C; Itimu S; Salima A; Chikasema M; Ward P; Mpasa A; Wachepa S; Mtete I; Butia M; Chasela M; Mtunda M; Wasswa P; Martin S; Kim NE; Kazembe P; Gopal S
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27353. PubMed ID: 30015407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
    Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
    JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.